Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs Care Bare Rx

Two GLP-1 desks, one scoreboard. We put MadeMed and Care Bare Rx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 38 · Grade C

Care Bare Rx

Visit Care Bare Rx Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 72 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make Care Bare Rx a bad call — it's best for readers who want an oral tirzepatide route or a brand pathway and will complete an intake to learn the cost. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
72
Supply Reliability
84
80
Transparency
94
52
Access Breadth
76
88
Clinical Oversight
84
70
Track Record
82
72
MadeMedBrief Score 86 · 72Care Bare Rx

Price, coverage & the tracker

MadeMedCare Bare Rx
Brief Score86/100 (B)72/100 (C)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)From $199/mo (shared figure) · brand Ozempic from $705/mo
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)Not separately disclosed
Coverage40 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
On the trackerStableprice stableStableprice stable

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Care Bare Rx: One "$199" covers all weight-loss treatments; per-dose rates stay behind the intake quiz.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.